MYLAN-PAROXETINE DIN 02248013
Status: Cancelled Post Market
Holder: MYLAN PHARMACEUTICALS ULC
Health Canada record
| Active ingredient(s) | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 20 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AB05 PAROXETINE |
| Original market date | 08-Oct-2003 |
| Current status date | 12-Jul-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Mylan Pharmaceuticals ULC — licence 101774, currently licensed, last inspection rating C (2026-02-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02248014 | MYLAN-PAROXETINE | MYLAN PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 30 MG | Cancelled Post Market |
| 02248012 | MYLAN-PAROXETINE | MYLAN PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 10 MG | Cancelled Post Market |
| 02338807 | Q-PAROXETINE | QD PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 20 MG | Cancelled Post Market |
| 02338815 | Q-PAROXETINE | QD PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 30 MG | Cancelled Post Market |
| 02338793 | Q-PAROXETINE | QD PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 10 MG | Cancelled Post Market |
| 02254778 | SANDOZ PAROXETINE | SANDOZ CANADA INCORPORATED | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 30 MG | Cancelled Post Market |
| 02254751 | SANDOZ PAROXETINE | SANDOZ CANADA INCORPORATED | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 10351 | 2009-07-09 | Abbreviated New Drug Submission (ANDS) | Manufacturer and product name change |
| 3454 | 2003-10-08 | Abbreviated New Drug Submission (ANDS) |